PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. 
Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients.  To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients.  Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included.  Achievement of Psoriasis Area Severity Index (PASI), PASI 90/100 response and time taken to achieve PASI 90/100 response were measured.  Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI 100 response.  Two hundred and fifty five patients were included.  No difference was observed in PASI 90 response between etanercept and ustekinumab (65.5 vs. 55.4%), while adalimumab-treated patients had a higher response versusustekinumab (71.6 vs. 55.4%, p = .02).  More patients achieved complete remission (PASI 100 response) with adalimumab versus etanercept (65.7 vs. 23%, p < .001) or ustekinumab (65.7 vs. 44.6%, p = .003).  Adalimumab-treated patients achieving PASI 90 responded more quickly (by three and six months) versus ustekinumab or etanercept.  PASI100 response was achieved in ∼43% of adalimumab and ustekinumab treated-patients by three months versus etanercept (14.3%), increasing to 92.5, 85.4 and 35.7%, respectively by six months.  PASI100 response was associated with psoriasis nail involvement or genital psoriasis.  In the real-life setting, adalimumab was the most effective biological agent for the treatment of plaque psoriasis.